leadf
logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics gears up for phase 3 funding deal

Phase 3 data from Ridinilazole is set to come out in the second half of 2021, with the antibiotic already shown to kill C.difficile infections while preserving healthy microorganisms in the gastrointestinal tract

Summit Therapeutics PLC -

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) is ramping up funding and commercial preparations as it gears up for a Phase 3 trial of its lead product.

Summit’s chief executive Glyn Edwards said the company remains on track to deliver Phase 3 data for ridinilazole in the second half of 2021, having shown in Phase 2 trials that the drug could kill C.difficile infections while preserving healthy microorganisms in the gastrointestinal tract.

After making a third-quarter loss of £7mln compared to £8.1mln in the same period last year, the AIM-listed company had a cash balance of £13.6mln at 31 October, not including a proposed US$50mln fundraise from biotech billionaire Bob Duggan, which will go to a shareholder vote on 23 December.

The fundraise would give the company enough capital to take ridinilazole through phase III trials.

Summit’s income was boosted during the quarter by its funding contract with the US Biomedical Advanced Research and Development Authority (BARDA) for the development of ridinilazole, which awarded £3.6mln in the last quarter.

Shares were down almost 3% at 20.4p in early afternoon trading on Tuesday.

Quick facts: Summit Therapeutics PLC

Price: 4.34 USD

NASDAQ:SMMT
Market: NASDAQ
Market Cap: $357.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

on 10/2/20

2 min read